

LIAISON NES[®]

A molecular diagnostic device purpose-built
for point-of-care.

Fast reliable answers in ~15 minutes

Accurate, same-visit results for
viral and bacterial respiratory
infections that enable confident
patient care decisions.

CLIA-
Waived

Diasorin



Simplify respiratory infection testing with the LIAISON NES®.

LIAISON NES® enables non-laboratory staff to consistently get accurate results for respiratory illnesses in ~15 minutes. It's a simple device that's easy-to-learn, easy-to-use, and easy-to-maintain.



Point-of-care respiratory testing is associated with:

↓ **25%**

reduction in emergency department length of stay¹

↓ **70%**

avoided unnecessary antibiotics after RSV-positive test²

↓ **60%**

decrease in time to treatment for flu infections³

↓ **44%**

fewer antibiotic prescriptions in group A strep-negative patients⁴

93% patients believe that point-of-care testing can improve their care.⁵

Molecular confidence combined with CLIA-waived simplicity

LIAISON NES® FLU A/B, RSV & COVID-19

NASAL SWAB

Up to **99.8%**

Positive percent agreement⁶

Up to **98.4%**

Negative percent agreement⁶

LIAISON NES® GROUP A STREP

THROAT SWAB

100%

Sensitivity⁷

95.9%

Specificity⁷

Make confident, same-visit clinical decisions

<1

minute
hands-on time

3

steps to
run testing

~15

minutes
turnaround time*

**NO CONFIRMATORY
TESTING REQUIRED**

Improve patient satisfaction, reduce infection spread, and promote antibiotic stewardship by enabling immediate test-and-treat care.

*Early call-out and termination for positives at ~13 minutes for group A strep

Simplify at every step

PURPOSE-BUILT FOR POINT-OF-CARE MOLECULAR TESTING.



Effortless implementation

- Complete training kit with controls included
- Sample collection kit included



On-demand readiness

- Room-temperature reagents for easy storage and access
- Firmware updates deployed remotely



Seamless connectivity

- Centralized management of devices
- LIS/EMR** integration capabilities



Gain clinical confidence without workflow complexity

with easy, reliable molecular testing that minimizes operator time, risk of errors, and manual steps.




Promote financial sustainability

with a molecular point-of-care solution that keeps testing in-house and delivers favorable payer coverage.

**LIS: laboratory information system; EMR: electronic medical record



Find out how the LIAISON NES® can fit into your workflow



ORDERING INFORMATION

Product Name	Kit Size	Part Number	CPT code
LIAISON NES® Instrument		NES1001	
LIAISON NES® FLU A/B, RSV & COVID-19 Assay	10	NES4450	87637
LIAISON NES® FLU A/B, RSV & COVID-19 Control Kit	20 (10 positive, 10 negative)	NES4460	
LIAISON NES® Group A Strep	10	NES2850	87651
LIAISON NES® Group A Strep Control Kit	20 (10 positive, 10 negative)	NES2860	
COPAN FLOQSwabs®	100	NES4001	

Get started at
diasorin.com/liaison-nes



REFERENCES:

1. Baron A, Peyrony O, Salmona M, et al. Impact of Fast SARS-CoV-2 Molecular Point-Of-Care Testing on Patients' Length of Stay in an Emergency Department. *Microbiol Spectr*. 2022 Aug 31;10(4):e0063622.
2. Ferruggia K. How Rapid RSV Testing Shapes Clinical Decisions and Patient Outcomes. Pharmacy Times. Published Nov 4, 2025. Accessed Feb 2026. Available at <https://www.pharmacytimes.com/view/how-rapid-rsv-testing-shapes-clinical-decisions-and-patient-outcomes>
3. Martinot M, Greigert V, Gravier S, et al. Positive Impact of a Point-of-Care Molecular Influenza Test in the Emergency Department During the 2017-2018 Seasonal Influenza Epidemic. *Open Forum Infect Dis*. 2019;6(7):ofz312. doi:10.1093/ofid/ofz312
4. Dubois C, Smeesters PR, Refes Y, et al. Diagnostic accuracy of rapid nucleic acid tests for group A streptococcal pharyngitis: systematic review and meta-analysis. *Clin Microbiol Infect*. 2021;27(12):1736-1745. doi:10.1016/j.cmi.2021.04.021
5. Lilly CM, Ensom E, Teebagay S, DiMezza D, Dunlap D, Hafer N, Buchholz B, McManus D. Patient Preferences for Point-of-Care Testing: Survey Validation and Results. *Point Care*. 2020 Dec;19(4):112-115. doi:10.1097/poc.0000000000000214
6. LIAISON NES® Flu A/B, RSV & COVID-19 Instructions for Use. DiaSorin; 2026. IFUk.US.NES4450, Rev 1.
7. LIAISON NES® Group A Strep Instructions for Use. Diasorin; 2026. IFUk.US.NES2850, Rev 1.

Diasorin

CLIA COMPLEXITY: WAIVED

Refer to the LIAISON NES® FLU A/B, RSV & COVID-19 Instructions for Use and LIAISON NES® Group A Strep Instructions for Use for complete instructions.

For In Vitro Diagnostic Use. Products are region specific and may not be approved in some countries/regions.

©2026 DiaSorin Molecular LLC. All rights reserved. LIAISON and LIAISON NES are trademarks of of DiaSorin Molecular LLC and/or its affiliates, registered in the US and other countries.

BR1129102.US.0226